| Literature DB >> 27030047 |
Abstract
BACKGROUND: Considering the prevalence of obesity in society it can be expected that some adolescents with an eating disorder (ED) start weight loss from an overweight and present at a near-normal weight. Presently, the influence of premorbid BMI on clinical characteristics of adolescent girls presenting with an ED has ben studied.Entities:
Keywords: Adolescent; Eating disorder; Obesity; Overweight; Premorbid weight
Mesh:
Year: 2016 PMID: 27030047 PMCID: PMC4815196 DOI: 10.1186/s12888-016-0788-7
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Fig. 1Body mass index (BMI) standard deviation score at the maximal premorbid weight of 275 postmenarcheal adolescent girls presenting with an eating disorder. BMI SDS = 0 (solid line represents the population average. The average of the present sample (BMI SDS 0,73 ± 1,00; mean ± SD) is indicated by the dotted line
Anthropometric measurements, selected clinical and laboratory variables, and self-report instruments in 275 postmenarcheal adolescent girls presenting with an eating disorder
| Premorbid BMI SDS class | 1 | 2 | 3 | 4 | 5 |
|
|---|---|---|---|---|---|---|
| N | 11 | 60 | 100 | 79 | 25 | |
| Prepubertal age (years) | 7,5 ± 0,7 | 7,3 ± 1,0 | 7,3 ± 1,0 | 7,2 ± 0,8 | 7,4 ± 0,6 | NS |
| Prepubertal BMI SDS | −0,73 ± 0,76 | −0,12 ± 0,79 | 0,60 ± 0,85 | 1,31 ± 0,78 | 1,76 ± 0,82 | <0,001 |
| Age at menarche (years) | 13,4 ± 1,12 | 12,7 ± 1,0 | 12,6 ± 1,0 | 12,3 ± 0,9 | 12,4 ± 0,8 |
|
| Age at documented top weight (year) | 15,4 ± 1,4 | 14,7 ± 1,3 | 14,7 ± 1,3 | 14,3 ± 1,4 | 14,3 ± 1,7 | NS |
| BMI SDS at documented top weight | −1,58 ± 0,62 | −0,28 ± 0,47 | 0,62 ± 0,44 | 1,43 ± 0,35 | 2,35 ± 0,43 | <0,001 |
| BMI SDS change from prepuberty to top weight | −0,83 ± 0,64 | −0,21 ± 0,78 | 0,01 ± 0,82 | 0,17 ± 0,76 | 0,68 ± 0,80 | <0,001 |
| Age at presentation (years) | 15,8 ± 1,3 | 15,4 ± 1,4 | 15,6 ± 1,3 | 15,3 ± 1,4 | 15,7 ± 1,4 | NS |
| Gynecological age (years) | 2,2 ± 1,5 | 2,7 ± 1,4 | 3,0 ± 1,4 | 3,0 ± 1,3 | 3,3 ± 1,4 | NS |
| Duration of eating disturbed symptoms (months) | 9 ± 12 | 9 ± 9 | 10 ± 10 | 10 ± 9 | 12 ± 11 | NS |
| BMI SDS at presentation | −2,79 ± 0,98 | −1,60 ± 0,72 | −0,61 ± 0,93 | −0,13 ± 1,01 | 0,46 ± 1,11 | <0,001 |
| Weight loss (kg) | 4,5 ± 3,8 | 5,0 ± 4,2 | 5,7 ± 4,9 | 9,5 ± 5,7 | 14,3 ± 7,9 | <0,001 |
| Rate of weight loss immediately preceding presentation (g/day) | 74 ± 68 | 44 ± 62 | 31 ± 61 | 52 ± 66 | 60 ± 69 | NS |
| Menstrual status (menses/amenorrhea/hormonal anticonception) | 6/4/1 | 26/27/7 | 52/30/18 | 38/28/13 | 20/3/2 | NS |
| (55/36/9 %) | (43/45/12 %) | (52/30/18 %) | (48/36/16 %) | (80/12/8 %) | ||
| Exercise as part of weight controlling behaviour | 8 (73 %) | 44 (73 %) | 73 (73 %) | 62 (79 %) | 19 (76 %) | NS |
| Vomiting as part of weight controlling behaviour | 1 (9 %) | 16 (27 %) | 33 (33 %) | 20 (25 %) | 7 (28 %) | NS |
| EDE-Q global score | 1,7 ± 1,7 | 2,6 ± 1,5 | 3,3 ± 1,7 | 3,2 ± 1,6 | 3,1 ± 1,6 |
|
| EDE-Q eating concerns | 1,7 ± 1,9 | 2,4 ± 1,8 | 2,9 ± 1,9 | 2,7 ± 1,8 | 2,6 ± 2,0 | NS |
| EDE-Q restraint | 1,3 ± 1,2 | 2,2 ± 1,4 | 2,7 ± 1,6 | 2,6 ± 1,5 | 2,6 ± 1,5 |
|
| EDE-Q shape concern | 2,2 ± 2,2 | 3,2 ± 1,8 | 4,1 ± 1,8 | 4,0 ± 1,9 | 3,9 ± 1,8 |
|
| EDE-Q weight concern | 1,8 ± 1,8 | 2,6 ± 1,7 | 3,4 ± 1,9 | 3,3 ± 1,8 | 3,2 ± 2,0 |
|
| MADRS-S | 13 ± 11 | 16 ± 10 | 21 ± 11 | 17 ± 10 | 20 ± 12 |
|
| Diagnoses (AN/BN/EDNOS) | 7/0/4 | 12/1/47 | 9/3/88 | 4/3/72 | 1/2/22 | p < 0,001 |
| (64/0/36 %) | (20/2/78 %) | (9/3/88 %) | (5/4/91 %) | (4/8/88 %) | ||
| Pulse rate | 58 ± 9 | 61 ± 8 | 63 ± 7 | 62 ± 7 | 63 ± 8 | NS |
| Systolic blood pressure | 99 ± 8 | 105 ± 9 | 106 ± 10 | 108 ± 11 | 110 ± 10 |
|
| Plasma potassium (mmol/L) | 4,3 ± 0,2 | 4,2 ± 0,3 | 4,2 ± 0,2 | 4,2 ± 0,3 | 4,3 ± 0,3 | NS |
| Plasma phosphate (mmol/L) | 1,18 ± 0,18 | 1,19 ± 0,17 | 1,19 ± 0,15 | 1,19 ± 0,15 | 1,21 ± 0,11 | NS |
| Serum free triodothyronine (pmol/L) | 3,5 ± 1,9 | 4,2 ± 1,3 | 4,2 ± 1,2 | 4,0 ± 1,2 | 4,0 ± 0,9 | NS |
| Serum insulin-like growth factor 1 (μg/L) | 227 ± 136 | 275 ± 116 | 308 ± 125 | 286 ± 132 | 310 ± 115 | NS |
| Serum luteinizing hormone (IU/L) | 0,43 ± 0,47 | 0,67 ± 0,74 | 0,89 ± 1,25 | 1,04 ± 1,53 | 0,86 ± 0,75 | NS |
Patients are grouped in one SDS wide classes according to the BMI SDS at their highest weight before the onset of the eating disorder. Class 1 represents premorbid BMI SDS
<−1,000, class 2 BMI SDS −1,000 - -0,001, class 3 BMI SDS 0–0,999, class 4 BMI SDS 1,000-1,999 and class 5 BMI SDS >1,999. Values are means ± SD. Statistical analyses are by one-sided ANOVA and Chi-square test for continuous and categorical variables, respectively
Reference values for laboratory parameters: Plasma potassium 3,7-4,8 mmol//L, plasma phosphate 0,94–1,63 mmol/L, serum free triiodothyronine 3,9–7,7 pmol/L, serum insulin-like growth factor 1 115–510 μg/L for age 12–15 years and 247–482 μg/L for age 16–20 years, serum luteinizing hormone >1 IU/L throughout the menstrual cycle but highly variable
BMI SDS BMI standard deviation score, AN anorexia nervosa, BN bulimia nervosa and subthreshold bulimia nervosa, EDNOS eating disorders not otherwise specified of restrictive subtype, EDE-Q eating disorders examination-questionnaire youth version; MADRS-S Montgomery-Åsberg depression rating scale-self report
Relationship between selected clinical and laboratory parameters and BMI SDS, total weight loss and rate of weight loss at assessment of 268 postmenarcheal adolescent girls presenting with an eating disorder
| Dependent variable | Independent variables | Beta | R2 |
|
|---|---|---|---|---|
| Pulse frequency | BMI SDS | 0,326 | 0,188 | <0,001 |
| Weight loss | −0,199 | 0,070 | <0,001 | |
| Final rate of weight loss | −0,189 | 0,027 |
| |
| Systolic blood pressure | BMI SDS | 0,311 | 0,152 | <0,001 |
| Weight loss | - | - | - | |
| Final rate of weight loss | −0,249 | 0,056 | <0,001 | |
| Plasma potassium | BMI SDS | - | - | - |
| Weight loss | - | - | - | |
| Final rate of weight loss | - | - | - | |
| Plasma phosphate | BMI SDS | - | - | - |
| Weight loss | −0,141 | 0,020 |
| |
| Final rate of weight loss | - | - | - | |
| Serum free triodothyronine | BMI SDS | 0,191 | 0,033 | <0,001 |
| Weight loss | −0,347 | 0,267 | <0,001 | |
| Final rate of weight loss | −0,315 | 0,107 | <0,001 | |
| Serum insulin-like growth factor 1 | BMI SDS | 0,260 | 0,073 | <0,001 |
| Weight loss | −0,245 | 0,048 | <0,001 | |
| Final rate of weight loss | −0,333 | 0,275 | <0,001 | |
| Serum luteinizing hormone | BMI SDS | 0,210 | 0,086 |
|
| Weight loss | - | - | - | |
| Final rate of weight loss | −0,227 | 0,040 |
|
The dependent variables were entered against BMI SDS, weight loss and the rate of weight loss immediately preceding assessment in a linear stepwise regression analysis
BMI SDS BMI standard deviation score